|
1. A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with a CNP agonist, comprising the step of administering to the patient a therapeutically effective amount of a controlled-release CNP agonist comprising a CNP moiety (-D) comprising a ring moiety, wherein the ring moiety has the amino acid sequence of SEQ ID NO:96, provided the methionine at position 11 of SEQ ID NO:96 can be substituted with asparagine, the ring moiety being between two cysteine residues forming a disulfide bridge, and being conjugated to a polymer via a reversible prodrug linker cleavable in aqueous buffer at pH 7.4 and 37° C. in the absence of enzymes with a half-life of up to six months, wherein the polymer is water-soluble and a branched polymer of at least 10 kDa, wherein the controlled-release CNP agonist on cleavage of the reversible prodrug linker releases -D in its free form (D-H) and wherein the controlled-release CNP agonist has an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released D-H.
|